A new preclinical study suggests that fructose may help ovarian cancer cells spread after chemotherapy by changing the way surviving tumour cells communicate with nearby cells.
The findings published in the Nature Aging, from researchers at The Wistar Institute in Pennsylvania, offer an early but potentially important clue about why ovarian cancer can recur or metastasise after treatment.
The research was carried out in laboratory experiments and animal models, not in patients. It does not show that eating fruit, sugar, or foods containing fructose causes ovarian cancer to spread in people.
“The researchers also reported that a high-fructose diet increased cancer spread in animal models, even without chemotherapy”
Still, the work raises questions about how chemotherapy-surviving cancer cells behave, how dietary sugars may interact with cancer biology, and whether medicines that alter fructose metabolism could one day become part of treatment strategies.
Ovarian cancer remains one of the most difficult gynaecological cancers to detect and treat. Symptoms can be subtle, non-specific, or absent in the earliest stages. Bloating, pelvic discomfort, changes in appetite, feeling full quickly, and urinary changes may be mistaken for less serious conditions. By the time many people receive a diagnosis, the disease has already spread within the abdomen or beyond it.
Ovarian cancer is the 4th most common cancer among women in Malaysia, accounting for roughly 5% to 7.2% of all female cancer cases. The incidence rate is about 7.3 to 7.6 per 100,000 women, with over 80% of cases diagnosed at an advanced stage (Stage 3 or above).
Survival has improved through advances in surgery, chemotherapy, genetic testing, targeted medicines, and maintenance treatment. Yet the disease remains a major clinical challenge, especially when cancer returns after initial therapy.
Chemotherapy is a central part of treatment for many forms of ovarian cancer. It is often used after surgery to destroy cancer cells that cannot be removed, or before surgery to reduce tumour size in selected cases. However, chemotherapy does not eliminate every cancer cell in all patients. Some cells survive treatment. Those surviving cells may contribute to relapse, treatment resistance, or metastatic spread.
The latest study focused on one possible explanation for this process: cellular senescence.
Senescence is a state in which cells remain alive but stop dividing. It is sometimes described as a biological “pause” or growth arrest. In cancer treatment, chemotherapy can push some tumour cells into this state rather than killing them completely. On the surface, that may appear helpful. A cell that does not divide cannot directly form more cancer cells.
The picture is more complicated.
Senescent cells can remain metabolically active. They can release a broad mix of molecules into their surroundings. These secreted substances can alter inflammation, tissue behaviour, immune responses, and the activity of nearby tumour cells. Scientists increasingly recognise that senescent cancer cells may influence disease progression even when they are no longer multiplying themselves.
In the new research, investigators exposed ovarian cancer cells to chemotherapy, collected cells that survived, and examined the signals released by them. They then exposed other ovarian cancer cells to those substances. The recipient cells showed a greater capacity to spread.
Animal-model experiments supported the laboratory findings. Cancer cells exposed to signals from chemotherapy-surviving cells appeared more able to disseminate, suggesting that the after-effects of treatment may affect tumour behaviour in ways that deserve closer scrutiny.
The key signal identified by the researchers was fructose.
Fructose is a naturally occurring sugar found in fruit, honey, and some vegetables. It is also widely present in added sugars, particularly high-fructose corn syrup and sweetened processed foods and drinks.
The study did not identify fructose as a simple dietary villain. Instead, it described fructose as a metabolic messenger released by cancer cells that had survived chemotherapy.
According to the researchers, this fructose could be taken up and processed by neighbouring ovarian cancer cells. That process appeared to reduce cholesterol production within those cells. Lower cholesterol levels then weakened a form of cellular cohesion, making it easier for cancer cells to detach from one another.
That detachment matters in metastasis (cancer spreading).
For cancer to spread, cells often need to break away from the original tumour, survive in circulation or body fluid, travel to another area, and establish new growth.
Ovarian cancer commonly spreads through the abdominal cavity, including to the lining of the abdomen, bowel surfaces, liver capsule, diaphragm, and other nearby structures. Cell clusters can also circulate in abdominal fluid.
Cholesterol is often discussed in relation to cardiovascular health. At the cellular level, however, it has many other roles. It contributes to cell membranes and helps organise structures that enable cells to communicate and attach. In this study, reduced cholesterol production appeared to weaken the “glue” that keeps cancer cells together. The result was a greater ability to disperse and spread.
The researchers also reported that a high-fructose diet increased cancer spread in animal models, even without chemotherapy. This is a striking finding, though it must be interpreted carefully. Animal models are vital for studying cancer mechanisms, but they cannot fully reproduce the biology, diets, treatments, genetics, and clinical complexity of human patients.
No evidence from this study establishes that people with ovarian cancer should eliminate fruit from their diets. Fruit provides fibre, vitamins, minerals, water, and other compounds associated with healthier dietary patterns. The research also does not prove that a person’s intake of fructose directly determines whether their cancer will recur or spread.
The more immediate concern is likely to centre on high amounts of added sugars, especially from sugar-sweetened drinks and highly processed foods. These products can contribute substantial fructose without the fibre and nutritional value present in whole fruit. Even so, any dietary changes during cancer treatment should be discussed with an oncology team or a registered dietitian with cancer-care experience.
Cancer treatment can affect appetite, weight, taste, digestion, blood sugar, and nutritional needs. Some people require higher-calorie or higher-protein foods during treatment. Restrictive diets may be inappropriate or harmful, particularly for patients losing weight or struggling to eat. There is no one-size-fits-all cancer diet.
The study’s implications extend beyond food choices. It may point towards new treatment targets.
The scientists said they are examining whether an existing medicine used in diabetes could reduce fructose production by chemotherapy-surviving cells. The idea is not to replace chemotherapy. Rather, it is to understand whether a second treatment could block harmful metabolic changes that occur in cells left behind after chemotherapy.
That approach reflects a growing shift in cancer research. Scientists are not only studying how to kill tumour cells. They are also examining the state of cells that survive therapy. A surviving cell may be damaged, dormant, senescent, resistant, or metabolically altered. Each state could affect the tumour environment in a different way.
This kind of research may help explain why some cancers return despite an initially good response to treatment. It could also lead to treatments designed to remove senescent cancer cells, suppress their secreted signals, or prevent nearby cancer cells from responding to those signals.
The cholesterol finding also raises a complex question about statins, a common class of medicines used to lower blood cholesterol and reduce cardiovascular risk. The study does not show that statins worsen ovarian cancer outcomes. It does not show that patients should stop, start, or change cholesterol medicines because of these findings.
Statins affect cholesterol metabolism throughout the body, while the new research concerns a specific pathway within cancer cells in experimental systems. The interaction between cholesterol-lowering medicines, tumour-cell cholesterol production, chemotherapy response, and metastasis will require careful study in people before any clinical conclusions can be made.
Ovarian cancer specialists stressed that the results remain preliminary. The findings need validation in patient samples, clinical datasets, and eventually human trials. Researchers will need to determine whether fructose released by senescent tumour cells is detectable in patients, whether it predicts recurrence, and whether intervening in this pathway improves outcomes.
They will also need to investigate whether the mechanism applies to other cancers. The study authors suggested that related processes could be relevant in other abdominal malignancies, though this remains uncertain. Cancer metabolism differs markedly between tumour types and even between patients with the same diagnosis.
For now, standard ovarian cancer care remains unchanged. Treatment commonly involves surgery aimed at removing as much visible tumour as possible, followed by platinum-based chemotherapy. Depending on the type of cancer, its stage, genetic features, and response to treatment, patients may also receive targeted therapies such as PARP inhibitors, anti-angiogenic drugs, or other maintenance treatments.
Genetic testing has become particularly important in ovarian cancer. Inherited mutations in genes such as and can raise risk and may influence treatment decisions. Tumour testing can also identify changes that guide the use of targeted medicines. People with a strong family history of ovarian, breast, pancreatic, prostate, or related cancers may benefit from genetic counselling.
There is no reliable routine screening test for ovarian cancer in the general population. This makes awareness of persistent symptoms and individual risk factors especially important. People with symptoms that are new, frequent, worsening, or lasting several weeks should seek medical advice, particularly if they have a family history of relevant cancers.
Risk reduction is also an important part of the broader picture. There is no guaranteed way to prevent ovarian cancer. Evidence suggests that factors such as oral contraceptive use, pregnancy, breastfeeding, and certain gynaecological surgeries may reduce risk in some circumstances. For people with high-risk inherited genetic mutations, risk-reducing surgery may be considered after personalised counselling.
A healthy lifestyle supports general wellbeing and may lower the risk of several diseases. This usually means regular physical activity, avoiding tobacco, maintaining a weight that is appropriate for the individual, and choosing a diet based mainly on minimally processed foods.
Vegetables, fruit, legumes, whole grains, nuts, seeds, and healthy fats can form part of that pattern. Limiting sugary drinks and highly processed foods is reasonable for most people, though it should not be presented as a substitute for cancer treatment.
The new findings add an intriguing piece to a much larger scientific puzzle. They suggest that chemotherapy-surviving ovarian cancer cells may do more than persist quietly. They may release fructose, remodel the metabolic environment around them, reduce cellular cholesterol, and make neighbouring tumour cells more capable of moving and spreading.
That is not yet a change in clinical practice. It is, however, a credible new direction for research into one of ovarian cancer’s most urgent problems which is preventing metastasis and recurrence after treatment.
The post This Type of Sugar May Fuel Ovarian Cancer Spread After Chemotherapy, Study Suggests first appeared on PP Health Malaysia.
